Publications by authors named "JJ Michiels"

Claim this Profile
A
Analysis of von Willebrand Disease in the "Heart of Europe".
Inge Vangenechten, Petr Smejkal, Jiri Zavrelova, Ondrej Zapletal, Alexander Wild, Jan Jacques Michiels

TH Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study.
Inge Vangenechten, Petr Smejkal, Ondrej Zapletal, Jan Jacques Michiels, Zwi Berneman

Thromb Haemost· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
I Vangenechten, K Mayger, P Smejkal, O Zapletal, J J Michiels

J Thromb Haemost· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
Jan Jacques Michiels, Petr Smejkal, Miroslav Penka, Angelika Batorova, Tatiana Pricangova

Clin Appl Thromb Hemost· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe Exclusion of Deep Vein Thrombosis by a Rapid Sensitive ELISA D-dimer and Compression Ultrasonography in 1330 Outpatients With Suspected DVT.
Jan Jacques Michiels, Hanny Maasland, Wim Moossdorff, Mildred Lao, Alain Gadiseur

Angiology· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.
Jan Jacques Michiels, Mihaela Tevet, Adrian Trifa, Emilia Niculescu-Mizil, Anca Lupu

Maedica (Bucur)· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis, etiology and management of the Budd-Chiari Syndrome: a bloodcoagulation and hepatological study on the course of the disease treated with TIPS.
Petr Dulíček, Petr Hůlek, Antonin Krajina, Ondrej Renc, Václav Šafka, Jan J Michiels

Int Angiol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients.
Jan Jacques Michiels

World J Crit Care Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Jan Jacques Michiels, Zwi Berneman, Wilfried Schroyens, Hendrik De Raeve

Acta Haematol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Jan Jacques Michiels, Achille Pich, Hendrik De Raeve, Alain Gadisseur

Acta Haematol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Jan Jacques Michiels, Zwi Berneman, Alain Gadisseur, King H Lam, Hendrik De Raeve

Acta Haematol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of deep vein thrombosis, and prevention of deep vein thrombosis recurrence and the post-thrombotic syndrome in the primary care medicine setting anno 2014.
Jan Jacques Michiels, Janneke Maria Michiels, Wim Moossdorff, Mildred Lao, Hanny Maasland

World J Crit Care Med· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Ulrich Geisen, Barbara Zieger, Lea Nakamura, Andreas Weis, Jürgen Heinz, Jan Jacques Michiels

Thromb Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duplex ultrasound, clinical score, thrombotic risk, and D-dimer testing for evidence based diagnosis and management of deep vein thrombosis and alternative diagnoses in the primary care setting and outpatient ward.
J J Michiels, W Moosdorff, H Maasland, J M Michiels, M U Lao

Int Angiol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiopathology, etiologic factors, diagnosis, and course of polycythemia vera as related to therapy according to william dameshek, 1940-1950.
Jan Jacques Michiels, Goodheart Institute And Foundation, Freedom Of Science And Education Thrombocythemia Vera Study Group, Tvsg And European Working Groups On Myeloproliferative Neoplasms Ewg Mpn

Turk J Haematol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
Reinhard Schneppenheim, Jan Jacques Michiels, Tobias Obser, Florian Oyen, Antje Pieconka

Blood· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory diagnosis and molecular classification of von Willebrand disease.
Alain Gadisseur, Cedric Hermans, Zwi Berneman, Wilfried Schroyens, Hans Deckmyn, Jan Jacques Michiels

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Jan Jacques Michiels, Zwi Berneman, Alain Gadisseur, Marc van der Planken, Wilfried Schroyens

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
Jan Jacques Michiels, Alain Gadisseur, Marc van der Planken, Wilfried Schroyens, Zwi Berneman

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Jan Jacques Michiels, Alain Gadisseur, Inge Vangenegten, Wilfried Schroyens, Zwi Berneman

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Alain Gadisseur, Zwi Berneman, Wilfried Schroyens, Jan Jacques Michiels

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Alain Gadisseur, Marc van der Planken, Wilfried Schroyens, Zwi Berneman, Jan Jacques Michiels

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Jan Jacques Michiels, Huub H D M van Vliet

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Jan Jacques Michiels, Huub H D M van Vliet, Zwi Berneman, Wilfried Schroyens, Alain Gadisseur

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Christoph Sucker, Jan Jacques Michiels, Rainer B Zotz

Acta Haematol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis